The impact of lung cancer on survival of idiopathic pulmonary fibrosis

Chest

Volumn 147, Issue 1, 2015, Pages 157-164

  Tomassetti, Sara ^a   Gurioli, Christian ^a   Ryu, Jay H ^b   Decker, Paul A ^b   Ravaglia, Claudia ^a   Tantalocco, Paola ^a   Buccioli, Matteo ^a   Piciucchi, Sara ^a   Sverzellati, Nicola ^c   Dubini, Alessandra ^a   Gavelli, Giampaolo ^d   Chilosi, Marco ^d   Poletti, Venerino ^a,e  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e U O Pneumologia G B Morgagni Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EMPYEMA; FEMALE; FIBROSING ALVEOLITIS; HEART FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; HYPOTENSION; INCIDENCE; LARGE CELL LUNG CARCINOMA; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG EMPHYSEMA; LUNG FIBROSIS; MALE; MIDDLE AGED; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PANCYTOPENIA; PNEUMOTHORAX; PREVALENCE; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RESPIRATORY FAILURE; SEPTIC SHOCK; SMALL CELL LUNG CANCER; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; COMPLICATION; FOLLOW UP; ITALY; LUNG NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; TRENDS;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84920735730     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0359     Document Type: Article

References (32)

1. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007; 101 (12): 2534-2540.
2. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995; 45 (12): 925-932.
3. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980; 35 (7): 496-499.
4. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14 (5): 723-728.
5. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011; 16 (2): 326-331.
6. Chilosi M, Doglioni C, Murer B, Poletti V. Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. S arcoidosis Vasc Diffuse Lung Dis. 2010; 27 (1): 7-18.
7. Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res. 2013; 162 (3): 156-173.
8. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev. 2013; 22 (129): 265-272.
9. Casoni GL, Ulivi P, Mercatali L, et al. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. I nt J Biol Markers. 2010; 25 (4): 229-235.
10. Kishi K, Homma S, Kurosaki A, Motoi N, Yoshimura K. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 2006; 30 (1): 95-99.
11. Chilosi M, Tomassetti S, Dubini A, et al. Immunophenotypic profiles of lung carcinomas associated with idiopathic pulmonary fibrosis. Paper presented at: European Respiratory Society Annual Meeting; 2008; Berlin, Germany.
12. Sakai S, Ono M, Nishio T, Kawarada Y, Nagashima A, Toyoshima S. Lung cancer associated with diffuse pulmonary fibrosis: CT-pathologic correlation. J Thorac Imaging. 2003; 18 (2): 67-71.
13. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. E ur Respir J. 2001; 17 (6): 1216-1219.
14. Sverzellati N, Wells AU, Tomassetti S, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnositc thin-section CT diagnoses. Radiology. 2010; 254 (3): 957-964.
15. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. M ayo Clin Proc. 2002; 77 (8): 763-770.
16. Calabrese F, Lunardi F, Giacometti C, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax. 2008; 63 (9): 795-802.
17. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.
18. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008; 136 (5): 1357-1363.
19. Fujimoto T, Okazaki T, Matsukura T, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg. 2003; 76 (5): 1674-1678.
20. Kushibe K, Kawaguchi T, Takahama M, Kimura M, Tojo T, Taniguchi S. Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg. 2007; 55 (8): 505-508.
21. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003; 125 (6): 1321-1327.
22. Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. A nn Thorac Surg. 2011; 92 (5): 1812-1817.
23. Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med. 2008; 26 (8): 504-507.
24. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013; 82 (2): 260-265.
25. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011; 71 (1): 70-74.
26. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010; 15 (1): 88-92.
27. Watanabe N, Taniguchi H, Kondoh Y, et al. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. I nt J Clin Oncol. 2014; 19 (2): 260-265.
28. Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. R espiration. 2013; 85 (4): 326-331.
29. Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapyrelated exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011; 6 (7): 1242-1246.
30. Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. A m J Respir Crit Care Med. 2007; 176 (7): 636-643.
31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228-247.
32. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012; 156 (10): 684-691.